T. Rowe Price Associates
VBIV

T. Rowe Price Associates’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

T. Rowe Price Associates’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,997
Closed -$55K – 2972
2023
Q1 		$55K Hold
5,997
– – ﹤0.01% 2781
2022
Q4 		$70K Sell
5,997
-1,713
-22% -$30.2K ﹤0.01% 2770
2022
Q3 		$165K Buy
7,710
+1,466
+23% +$39.5K ﹤0.01% 2607
2022
Q2 		$151K Buy
6,244
+1,724
+38% +$58.7K ﹤0.01% 2666
2022
Q1 		$225K Buy
4,520
+565
+14% +$27.9K ﹤0.01% 2671
2021
Q4 		$278K Buy
3,955
+253
+7% +$21.3K ﹤0.01% 2621
2021
Q3 		$345K Buy
3,702
+20
+0.5% +$1.9K ﹤0.01% 2528
2021
Q2 		$370K Buy
3,682
+79
+2% +$7.7K ﹤0.01% 2514
2021
Q1 		$336K Buy
3,603
+24
+0.7% +$2.43K ﹤0.01% 2526
2020
Q4 		$295K Buy
3,579
+340
+10% +$29K ﹤0.01% 2427
2020
Q3 		$278K Buy
3,239
+2,827
+686% +$329K ﹤0.01% 2319
2020
Q2 		$38K Buy
412
+59
+17% +$3.25K ﹤0.01% 2470
2020
Q1 		$10K Buy
+353
New +$13.7K ﹤0.01% 2499

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's VBIV Position: Q2 2023 in Review

T. Rowe Price Associates sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 5,997 shares — an estimated $55K sold.

T. Rowe Price Associates first reported a position in VBIV in Q1 2020 and held it in 13 quarters. The position peaked at $370K in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • T. Rowe Price Associates reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 5,997 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $55K.
  • T. Rowe Price Associates first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2020 and held it in 13 quarters.
  • T. Rowe Price Associates's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $370K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.